Fig. 2From: Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trialKaplan-Meier DDFS curves for patients treated in the short (9 weeks trastuzumab) vs the long (1 year trastuzumab) arm according to stage categories: anatomic stage I patients (a), prognostic stage I patients (b), prognostic stage IA patients (c)Back to article page